Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer

Keyphrases

• Adjuvant Chemotherapy Regimens 33%
• Adjuvant Systemic Therapy 100%
• Adjuvant Targeted Therapy 33%
• Anti-human Epidermal Growth Factor Receptor 2 33%
• Antihormone Therapy 33%
• Aromatase Inhibitors 33%
• Breast Cancer 33%
• Breast Cancer Biology 33%
• Breast Cancer Subtypes 33%
• Breast-conserving Therapy 33%
• Chemotherapy 33%
• Clinical Trials 33%
• Cytotoxic Chemotherapy 33%
• Distinct Subtypes 33%
• Early Breast Cancer 100%
• Epidermal Growth Factor Receptor 33%
• Gene Expression Profiling 66%
• Hormone Receptor 33%
• Hormone Receptor-positive Breast Cancer 66%
• Hormone-positive 33%
• Human Epidermal Growth Factor Receptor 2/neu 100%
• Improved Survival 33%
• Inflammatory Breast Cancer 33%
• Inoperable Tumor 33%
• Neoadjuvant 66%
• Neoadjuvant Systemic Therapy 100%
• Oncogenic Drivers 33%
• Patient Outcomes 66%
• Pertuzumab 33%
• Receptor Status 33%
• Relapse Risk 33%
• Systemic Therapy 66%
• Therapeutic Strategies 33%
• Trastuzumab 33%
• Working Diagnosis 33%

Medicine and Dentistry

• Adjuvant Chemotherapy 12%
• Aromatase Inhibitor 12%
• Breast Cancer 100%
• Cancer Pathobiology 12%
• Chemotherapy Regimens 12%
• Clinical Trial 12%
• Cytotoxic Chemotherapy 12%
• Disease 25%
• Epidermal Growth Factor Receptor 2 37%
• Gamma Urogastrone 37%
• Gene Expression Profiling 25%
• Hormone Receptor 37%
• Inflammatory Breast Cancer 12%
• Neoplasm 12%
• Pertuzumab 12%
• Receptor 12%
• Systemic Therapy 100%
• Tamoxifen 12%
• Targeted Therapy 12%
• Trastuzumab 12%